首页 文献索引 SCI期刊 AI助手
首页 正文

Respiratory investigation. 2025 May 16;63(4):633-638. doi: 10.1016/j.resinv.2025.05.005 N/A2.42024

Exploring factors associated with clinical remission in patients with severe asthma receiving anti-IL-4Rα, anti-IL-5/5R, or anti-IgE treatment

探究接受抗IL-4Rα、抗IL-5 / 5R或抗IgE治疗的重度哮喘患者的临床缓解因素 翻译改进

Shota Takahashi  1, Naoya Tanabe  2, Satoshi Marumo  3, Yu Hara  4, Yusuke Hayashi  5, Shinya Tsukamoto  5, Kyohei Morita  1, Chie Yoshimura  1, Moon Hee Hwang  1, Hironobu Sunadome  5, Atsuyasu Sato  5, Kota Murohashi  4, Takeshi Kaneko  4, Hisako Matsumoto  6, Toyohiro Hirai  5

作者单位 +展开

作者单位

  • 1 Department of Respiratory Medicine, Osaka Red Cross Hospital, 5-30 Fudegasakicho, Tennoji Ward, Osaka, 543-8555, Japan.
  • 2 Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. Electronic address: ntana@kuhp.kyoto-u.ac.jp.
  • 3 Respiratory Disease Center, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, 2 Chome-4-20 Ogimachi, Kita Ward, Osaka, 530-8480, Japan.
  • 4 Department of Pulmonology, Yokohama City University Graduate School of Medicine, 3 Chome-9 Fukuura, Kanazawa Ward, Yokohama, Kanagawa, 236-0004, Japan.
  • 5 Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  • 6 Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan; Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, 377-2 Onohigashi, Osakasayama, Ōsaka, 589-0014, Japan.

    • DOI: 10.1016/j.resinv.2025.05.005 PMID: 40381526

    摘要 中英对照阅读

    Background: The optimal selection of biologics is critical for achieving clinical remission (CR) in patients with severe asthma. This real-world study examined baseline prebiologic factors associated with CR in patients with severe asthma receiving anti-IL-4Rα, anti-IL-5/5R, or anti-IgE treatment.

    Methods: This Japanese multicenter retrospective observational study included consecutive patients with severe asthma whose spirometry and asthma control test (ACT) data were available after at least 1 year of anti-IL-4Rα, anti-IL-5/5R, or anti-IgE treatment. The 3-domain CR was defined based on no maintenance oral corticosteroid (OCS) use, no exacerbation in the previous year, and ACT ≥23. The 4-domain CR was defined based on no OCS, no exacerbation, ACT ≥20, and percentage-predicted forced expiratory volume in 1 s ≥ 80 %.

    Results: A total of 236 patients with severe asthma were included (n = 81, 104, and 51 for the anti-IL-4Rα, anti-IL-5/5R, and anti-IgE treatment groups, respectively). The rates of 3- and 4-domain CR were 28-47 % and 22-36 %, respectively. In the multivariate models, the presence of chronic rhinosinusitis and higher FeNO levels were associated with 3-domain CR in patients receiving anti-IL-4Rα treatment but not in those receiving anti-IL-5/5R or anti-IgE treatment after adjusting for baseline OCS use, past-year exacerbation history, body mass index, sex, and disease duration. Moreover, higher FeNO levels were associated with 4-domain CR in patients receiving anti-IL-4Rα treatment after adjustment for the same variables.

    Conclusion: Anti-IL-4Rα treatment may be effective for patients with severe asthma who have chronic rhinosinusitis or high FeNO levels at baseline.

    Keywords: Biologics; Clinical remission; Exacerbation; Severe asthma.

    Keywords：severe asthma; treatment; response; factors

    背景： 生物制剂的最优选择对于实现严重哮喘患者的临床缓解（CR）至关重要。本真实世界研究考察了在使用抗IL-4Rα、抗IL-5/5R或抗IgE治疗后，基线期前生物制剂因素与严重哮喘患者临床缓解的相关性。

    方法： 这项日本多中心回顾性观察研究包括了一组连续的严重哮喘患者，其肺功能和哮喘控制测试（ACT）数据在至少一年的抗IL-4Rα、抗IL-5/5R或抗IgE治疗后可获得。3领域临床缓解定义为无维持口服皮质类固醇（OCS）使用、过去一年内无恶化以及ACT得分≥23分。4领域临床缓解则在前者的前提下，再附加FEV1预测百分比≥80%的条件。

    结果： 总共纳入了236名严重哮喘患者（分别接受抗IL-4Rα、抗IL-5/5R和抗IgE治疗的患者数为81、104和51）。3领域和4领域临床缓解率分别为28%-47%和22%-36%。在多变量模型中，慢性鼻窦炎的存在以及较高的FeNO水平与接受抗IL-4Rα治疗患者的3领域临床缓解有关，但在调整基线OCS使用、过去一年内的恶化历史、体质指数、性别及疾病持续时间后，这些因素在接受抗IL-5/5R或抗IgE治疗的患者中则无关。此外，在考虑相同变量的情况下，较高的FeNO水平与接受抗IL-4Rα治疗患者的4领域临床缓解有关。

    结论： 对于基线时有慢性鼻窦炎或高FeNO水平的严重哮喘患者，抗IL-4Rα治疗可能是有效的。

    关键词： 生物制剂；临床缓解；恶化；重度哮喘。

    关键词：重度哮喘; 治疗; 反应; 因素

    翻译效果不满意？ 用Ai改进或 寻求AI助手帮助 ，对摘要进行重点提炼
    Copyright © Respiratory investigation. 中文内容为AI机器翻译，仅供参考！

    相关内容

    期刊名：Respiratory investigation

    缩写：

    ISSN：2212-5345

    e-ISSN：2212-5353

    IF/分区：2.4/N/A

    文章目录 更多期刊信息

    全文链接
    官方链接
    PMC全文
    引文链接
    复制
    已复制！
    推荐内容
    Exploring factors associated with clinical remission in patients with severe asthma receiving anti-IL-4Rα, anti-IL-5/5R, or anti-IgE treatment